CIPADI - Centro Integral de Prevención y Atención en Diabetes
CIPADI - Centro Integral de Prevención y Atención en Diabetes
FDF, Colón 776, M5504 Godoy Cruz, Mendoza, Argentina
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Pedro Calella
Maximo Andres Bornices
Maria Alicia Ferrandez
Natalia Manzano
Paula Ferrandez
Sherry Manzano
Laureano Guevara Civit
Open studies
Cardiovascular disease
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) - MOVE-Lp(a) - Eli Lilly and CompanySee more
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event - AZURE-Outcomes - AstraZenecaSee more
Obesity
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Renal disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
Elevated Lipoprotein A
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) - MOVE-Lp(a) - Eli Lilly and CompanySee more
